Table 1.
Primary pathway | Virus-derived facilitator (s) | Drug | Reference |
---|---|---|---|
AMPK | Unknown | Compound C, AICAR, ST0–609 | (4,5) |
mTOR | IE72, IE86, UL38 | Sirolimus, everolimus, rapamycin, torin | (9–12) |
CDKs | Unknown | Roscovitine | (21) |
PDGFR-α | gB (?) | Imatinib mesylate, IMC-3G3, | (2) |
PI3K | gB | LY294002 | (23) |
NF-κB | gB/gH, UL76, UL144, IE86 | BAY-11–7082, dexamethasone, lactacystin | (25–28,35,36) |
RAS/RAF/MEK1/2 | IE86, IE72 | Sorafenib, U0126, PD98059, FHPI | (38–41) |
UPR/proteasome degradation | US2, US11, pp71, UL38 | Clotrimazole | (51) |
WNT | Unknown | Monensin, nigericin, salinomycin | (56) |
AMPK, AMP-activated protein kinase; CDKs, cyclin-dependent kinases; mTOR, mammalian target of rapamycin; NF-κB, nuclear factor kappa beta; PDGFR-α, platelet-derived growth factor receptor-α; PI3K, phosphatidylinositol-3-kinase; UPR, unfolded protein response.